In VivoBiopharma financing during the third quarter of 2024 totaled $17bn from 207 deals. Of those, 54 reached $100m or more. The follow-on public offering (FOPO) category made up the made up most (34%) of t
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Crown Will Offer $924m To Merge With Re
Pink SheetA decade after the US Food and Drug Administration required makers of extended-release and long-acting opioid analgesics to conduct a post-marketing study on the risk of opioid-induced hyperalgesia, m
ScripMineralys Therapeutics, Inc. , which launched the largest biopharmaceutical company initial public offering so far this year late on 9 February, was an ideal IPO candidate under current market conditi